[HTML][HTML] B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients
AE Lovett-Racke, M Gormley, Y Liu, Y Yang… - Journal of …, 2019 - Elsevier
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, thought to
be mediated by myelin-specific CD4+ T cells. However, B cell depletion has proven to be an
effective therapy for MS, but the mechanism is not well understood. This study was designed
to determine how B cell depletion changes lymphocyte profiles. During a phase IIa clinical
trial with ublituximab, a novel CD20 antibody, blood was collected from 48 MS patients at 11
time points over 24 weeks and the lymphocyte profiles were analyzed by flow cytometry. The …
be mediated by myelin-specific CD4+ T cells. However, B cell depletion has proven to be an
effective therapy for MS, but the mechanism is not well understood. This study was designed
to determine how B cell depletion changes lymphocyte profiles. During a phase IIa clinical
trial with ublituximab, a novel CD20 antibody, blood was collected from 48 MS patients at 11
time points over 24 weeks and the lymphocyte profiles were analyzed by flow cytometry. The …